Topical Sodium Thiosulfate: A Treatment for Calcifications in Hyperphosphatemic Familial Tumoral Calcinosis?

被引:29
|
作者
Jost, Jeremy [1 ]
Bahans, Claire [2 ]
Courbebaisse, Marie [4 ]
Tu-Anh Tran [5 ]
Linglart, Agnes [6 ]
Benistan, Karelle [7 ]
Lienhardt, Anne [2 ]
Mutar, Hadile [2 ]
Pfender, Elodie [3 ]
Ratsimbazafy, Voa [1 ]
Guigonis, Vincent [2 ,8 ]
机构
[1] Com HME Rech Clin Ctr Hosp Univ, Pharm, F-87000 Limoges, France
[2] Com HME Rech Clin Ctr Hosp Univ, Univ Limoges,Ctr Hosp Univ Limoges,INSERM, Inst Epidemiol Neurol & Neurol Trop,UMRS 1094, Ctr Natl Rech Sci Federat Rech Genom Environm Imm, F-87000 Limoges, France
[3] Ctr Hosp Univ, Ctr Invest Clin, F-87000 Limoges, France
[4] Hop Europeen Georges Pompidou, AP HP, Dept Physiol, F-75000 Paris, France
[5] Ctr Hosp Univ Nimes, Pediat, F-30000 Nimes, France
[6] AP HP, Ctr Reference Malad Rare Metab Phosphocalc & Plat, F-94270 Le Kremlin Bicetre, France
[7] Hop Raymond Poincare, Genet Med, F-92380 Garches, France
[8] Univ Limoges, CNRS, UMR 7276, F-87000 Limoges, France
关键词
OF-THE-LITERATURE; UREMIC ARTERIOLOPATHY; CALCIPHYLAXIS; GALNT3; MANAGEMENT; PHOSPHATE; MUTATION; ACETAZOLAMIDE; ACIDOSIS; THERAPY;
D O I
10.1210/jc.2016-1087
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Hyperphosphatemic familial tumoral calcinosis (HFTC) and hyperphosphatemia hyperostosis syndrome (HHS) are rare diseases characterized by hyperphosphatemia and ectopic calcifications or recurrent episodes of diaphysitis. In the setting of metabolic or inflammatory diseases, recent data suggest that systemic administration of sodium thiosulfate (STS) could be effective in the treatment of ectopic calcifications but may also be poorly tolerated (digestive symptoms, metabolic acidosis). Our group developed a topical formulation of STStotreat ectopiccalcifications locally, therefore limiting patient exposure to the drug and its adverse effects. Objective: We aimed at describing efficacy and tolerance fora topical formulation of STS in treated patients. Design: We performed a retrospective study wherein clinical, radiological, and biological data before and after the application of the topical STS treatment were collected and analyzed. Patients or Other Participants: Three patients admitted to 3 different hospitals with an ectopic calcification secondary to HFTC or HHS were treated with topical STS. Intervention: The topical STS was applied daily by the patients. Results: A significant clinical and radiological decrease of ectopic calcifications was observed after at least 5 months of treatment. The STS treatment was well tolerated and no clinical or biological side effects were observed. Conclusion: Topical STS appears to be a promising treatment for ectopic calcifications secondary to HFTC or HHS.
引用
收藏
页码:2810 / 2815
页数:6
相关论文
共 50 条
  • [21] GALNT3 Mutation in Hyperphosphatemic Familial Tumoral Calcinosis - Novel Etiology of Secondary Amyloidosis
    Sharma, Sourabh
    Arora, Sahil
    Binoy, Renju
    Agarwal, Anupam
    Prasad, Pallavi
    Verma, Himanshu
    INDIAN JOURNAL OF NEPHROLOGY, 2025, 35 (02) : 303 - 305
  • [22] Iatrogenic Calcinosis Cutis Successfully Treated with Topical Sodium Thiosulfate
    Garcia-Garcia, Emilio
    Lopez-Lopez, Rocio
    Alvarez-del-Vayo, Concepcion
    Bernabeu-Wittel, Jose
    PEDIATRIC DERMATOLOGY, 2017, 34 (03) : 356 - 358
  • [23] Sodium thiosulphate treatment of uraemic tumoral calcinosis
    Malbos, Stephanie
    Urena-Torres, Pablo
    Cohen-Solal, Martine
    Trout, Herve
    Liote, Frederic
    Bardin, Thomas
    Ea, Hang-Korng
    RHEUMATOLOGY, 2014, 53 (03) : 547 - 551
  • [24] Clinical Characteristics, Therapeutic Options, and Outcomes in Hyperphosphatemic Tumoral Calcinosis: A Systematic Review
    Cherian, Kripa Elizabeth
    Cherian, Jacob
    Vinodhini, Dharmasivam
    Paul, Thomas Vizhalil
    CALCIFIED TISSUE INTERNATIONAL, 2024, 115 (03) : 215 - 228
  • [25] Linear amyopathic dermatomyositis with calcinosis cutis responsive to topical sodium thiosulfate
    Topham, Christina
    Haynes, Dylan
    Frigerio, Alice
    Hull, Christopher
    PEDIATRIC DERMATOLOGY, 2019, 36 (04) : E102 - E103
  • [26] A novel FGF23 mutation in hyperphosphatemic familial tumoral calcinosis and its deleterious effect on protein O-glycosylation
    Zuo, Qingyao
    Yang, Weili
    Liu, Baoyue
    Yan, Dong
    Wang, Zhixin
    Wang, Hong
    Deng, Wei
    Cao, Xi
    Yang, Jinkui
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [27] Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis
    Sun, Lihao
    Zhao, Lin
    Du, Lianjun
    Zhang, Peipei
    Zhang, Minjia
    Li, Min
    Liu, Tingting
    Ye, Lei
    Tao, Bei
    Zhao, Hongyan
    Liu, Jianmin
    Ding, Xiaoyi
    BONE RESEARCH, 2016, 4
  • [28] Structural and molecular imaging-based characterization of soft tissue and vascular calcification in hyperphosphatemic familial tumoral calcinosis
    Sheppard, Aaron J.
    Paravastu, Sriram S.
    Farhadi, Faraz
    Donnelly, Eve
    Hartley, Iris R.
    Gafni, Rachel, I
    Saboury, Babak
    Collins, Michael T.
    Roszko, Kelly L.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 (09) : 1327 - 1339
  • [29] Hyperphosphatemic tumoral calcinosis: a 10-year follow-up
    Alves, Cresio
    Lima, Renata
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2011, 24 (1-2) : 25 - 27
  • [30] Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies
    Roberts, Mary Scott
    Burbelo, Peter D.
    Egli-Spichtig, Daniela
    Perwad, Farzana
    Romero, Christopher J.
    Ichikawa, Shoji
    Farrow, Emily
    Econs, Michael J.
    Guthrie, Lori C.
    Collins, Michael T.
    Gafni, Rachel I.
    JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (12) : 5368 - 5373